Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kami-Untan-To + donepezil is a combination therapy consisting of Kami-Untan-To (also known as Kamiuntanto or KUT), a traditional Japanese Kampo herbal medicine, and donepezil, an acetylcholinesterase inhibitor. This combination has been studied for its potential synergistic effects in the treatment of Alzheimer's disease and dementia. Kami-Untan-To is composed of 13 crude herbal ingredients and is known to upregulate choline acetyltransferase (ChAT) expression and nerve growth factor mRNA levels in the brain, potentially enhancing cholinergic neurotransmission[2][4][6]. Donepezil works by inhibiting acetylcholinesterase, thereby increasing acetylcholine levels in the brain to improve cognitive function. Clinical studies suggest that combining these two agents may provide greater cognitive benefits than either agent alone and may increase cerebral blood flow in patients with Alzheimer's disease[5]. The combination represents an integration of Western pharmaceutical therapy with traditional Japanese medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kami-untan-to + donepezil.